New coronavirus infection COVID-19 in a patient after kidney allotransplantation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article describes a clinical case of a new covid-19 coronavirus infection in a patient receiving immunosuppressive therapy after allotransplantation of a cadaveric kidney. in the present observation, the course of covid-19 was manifested by bilateral pneumonia with respiratory failure, which required the use of active therapy with antiviral drugs, complicated by a nephrotoxic effect with the correction of immunosuppressive therapy.

Full Text

Restricted Access

About the authors

N. F. Frolova

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Email: nadiya.frolova@yandex.ru
PhD in Medical Sciences, Deputy Chief Physician for Nephrology Moscow, Russian Federation

S. S Usatyuk

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Head of the Nephrology Department № 2 Moscow, Russian Federation

L. Yu Artyukhina

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

PhD in Medical Sciences, Head of the Nephrology Department № 1 (Transplant Kidney Pathology) Moscow, Russian Federation

O. N. Kotenko

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

PhD in Medical Sciences, Head Moscow, Russian Federation

V. V Mayorov

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Doctor at the Nephrology Department № 2 Moscow, Russian Federation

M. A Lysenko

Moscow city research and practice center for Nephrology and pathology of transplanted kidneys Moscow City Hospital 52

Doctor of Medical Sciences, Chief Physician of the City Clinical Hospital № 52 of the Moscow Healthcare Department, Professor at the, Department of General Therapy, Faculty of Continuous Professional Education Moscow, Russian Federation

References

  1. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
  2. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
  3. de Wilde A.H., Zevenhoven-Dobbe J.C., van der Meer Y. et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J. Gen. Virol. 2011;92:2542-2548.
  4. Tanaka Y., Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5:1250-1260.
  5. Banerjee D., Popoola J., Shah S. et al. COVID-19 infection in kidney transplant recipients. Kidney International (2020):inpress 1-7.
  6. Cao B. et al. N. Engl. J. Med. 382, 1787-1799 (2020).
  7. Yao X., Ye F., Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020 March 9.
  8. J. Geleris Y., Sun J. Platt et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2020;382:1-7.
  9. Bhatraju P.K., Ghassemieh B.J., Michelle Nichols et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series N. Engl. J. Med. 2020;382:2012-2202.
  10. Mehta P., McAuley D.F., Brown M., Sanchez E., Tatter sail R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.
  11. Mark C. Genovese, James D. McKay, Evgeny L. Nasonov, Eduardo F. Mysler,Nilzio A. da Silva. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study// Arthritis and Rheumatism. 2008;58:2968-2980.
  12. Jones G, Sebba A., Gu J, Lowenstein M.B., Calvo A., Gomez-Reino J.J., Siri D.A., Tomsic M. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Annals of the Rheumatic Diseases. 2010 69(1):88-96.
  13. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies